Clin Osteol 2011; 16(1): 3-7

Effect of metoprolol on bone tissue in adult male Wistar ratsReview articles

I. Gradošová, K. Švejkovská, H. Živná, P. Živný, E. Čermáková, A. Tichý, V. Palička

Keywords: metoprolol, kostní markéry, DXA, testování mechanické odolnosti kostní tkáně, Western blot v SUMMARY

Published: June 11, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gradošová I, Švejkovská K, Živná H, Živný P, Čermáková E, Tichý A, Palička V. Effect of metoprolol on bone tissue in adult male Wistar rats. Osteologický bulletin. 2011;16(1):3-7.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Consensus development conference: Diagnosis, prophylaxis and treatment of os­ teoporosis. American Journal of Medicine 1991;94(6):646-650.
    2. Hvarfner A, Bergstrom R, Morlin C, Wide L, Ljunghall S. Relationships between calcium metabolic indices and blood pressure in patients with essential hyperten­ sion as compared with a healthy population. J Hypertens 1981;5(4):451-456. Go to original source...
    3. Izawa Y, Sagara K, Kadota T, Makita T. Bone disorders in spontaneously hyper­ tensive rat. Calcif Tissue Int 1985;31(6):605-601. Go to original source...
    4. McCarron DA, Pingree PA, Rubin RJ, Gaucher SM, Molitch M, Krutzik S. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension 1980;2(2):162-168. Go to original source...
    5. Vítovec J, Špinar J et al. Farmakoterapie kardiovaskulárních onemocnění. 2. vy­ dání. Praha, Grada, 2004:248.
    6. Robert E. Moore, Charles K. Smith II, Cathy S. Bailey, Edward F. Voelkel and Armen H. Tashjian Jr. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can sti­ mulate bone resorption in organ culture. Bone Miner 1993;23(3):301-315. 1. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111(3):305-311. Go to original source...
    7. Bonnet N, Pierroz DD, Ferrari SL. Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis. J Musculoskelet Neuronal Interact 2008;8(2):94-104.
    8. Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 2004;15(5):365-312. Go to original source...
    9. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE in­ hibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006;24(3):581-589. Go to original source...
    10. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA 2004;292(11):1326-1332. Go to original source...
    11. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mi­ neral density: Geelong Osteoporosis Study. J Bone Miner Res 2004;19(1):19-24. Go to original source...
    12. Meisinger C, Heier M, Lang O, Doring A Beta-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int 2001;18(9):1189-1195. Go to original source...
    13. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 1993;14(4):595-608. Go to original source...
    14. Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 2002;8(3):141-159. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.